- In 2018, BriaCell obtained topline safety and efficacy clinical data, achieved proof of concept and advanced its clinical program
- The company initiated patient dosing in a phase I/IIa clinical trial of its breast cancer immunotherapy Bria-IMT in combination with immune checkpoint inhibitors KEYTRUDA or YERVOY
- BriaCell is also working on the development of a personalized off-the-shelf immunotherapy treatment for advanced breast cancer that will potentially reduce the cost of tailor-made immunotherapy
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently announced the completion of several important milestones in 2018. These include obtaining topline safety and efficacy data in a clinical trial, achieving proof of concept and advancing the BriaCell clinical program.
Some of the most important information and data were included in a comprehensive report for Frontiers of Immunology, according to BriaCell CEO Dr. Bill Williams. The report highlights the complex mechanism in which targeted immunotherapy helps a patient’s immune system target cancer cells specifically.
BriaCell recently announced excellent safety and efficacy data from a phase I/IIa proof of concept clinical study in advanced breast cancer patients. There were reports of tumor shrinkage in various sites. These results were confirming the findings from two previous proof-of-concept clinical trials that showed promising results in patients with advanced breast cancer. The most notable result was observed in a patient whose breast cancer had metastasized. The patient responded to Bria-IMT, and substantial tumor shrinkage occurred. Shrinkage was observed in the breast, lungs, soft tissues and brain.
The immuno-oncology focused biotechnology company has already initiated patient dosing in a phase I/IIa clinical trial of its Bria-IMT, a breast cancer cell line that has been engineered to produce an immune-activating factor, in combination with immune checkpoint inhibitors pembrolizumab [KEYTRUDA; manufactured by Merck & Co., Inc. (NYSE: MRK)] or ipilimumab [YERVOY; manufactured by Bristol-Myers Squibb Company (NYSE: BMY)]. The study focuses on advanced breast cancer (http://ibn.fm/thGQd).
Immune checkpoint inhibitors such as KEYTRUDA and YERVOY boost the anti-tumor immune activity in cancer patients, and they recently came into the spotlight when the Nobel committee decided to award Dr. Tasuku Honjo and Dr. James P. Allison the 2018 Nobel Prize in Physiology or Medicine “for game-changing discoveries about how to harness and manipulate the immune system to fight cancer” (http://ibn.fm/3DZae). In an important pre-clinical study lead by Dr. Allison, KEYTRUDA and YERVOY significantly boosted the anti-tumor effects of an immunotherapeutic product designed similarly to Bria-IMT (http://ibn.fm/an8s4).
Bria-IMT stimulates the activity of T-cells that play a crucial role in the immune response. BriaCell expects KEYTRUDA and YERVOY to further amplify the anti-tumor activity of Bria-IMT, and it hopes to offer safe and effective treatment options to advanced breast cancer patients soon.
In addition to launching the new clinical trial, BriaCell is also focused on creating personalized off-the-shelf immunotherapy treatments that will eventually cover 90 percent of the patient population. According to Williams, such an approach will potentially revolutionize cancer immunotherapy.
BriaCell is the developer of the trademarked Bria-OTS – a personalized immunotherapy treatment for advanced breast cancer. The treatment is tailored to match the patient without the need for the execution of a personalized manufacturing process. The treatment produces a powerful selective immune response against the specific cancer. The treatment reduces the amount of time, expense and logistical processes currently required for the creation of personalized cancer immunotherapies.
Breast cancer is the most commonly occurring form of cancer in women and the second most common overall cancer, according to the World Cancer Research Fund. In 2018, there have been over two million new cases globally (http://ibn.fm/hdGX3).
Approximately 12.3 percent of women in the U.S. will receive the diagnosis at some point in their lifetime (http://ibn.fm/U4kCo). The good news is that the five-year survival rate for patients diagnosed with breast cancer has improved over time, going up from 74.8 percent in 1975 to 90.7 percent for those between 2004 and 2011.
For more information, visit the company’s website at www.BriaCell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
